Related Experiment Video
Updated: Sep 17, 2025
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
[Exploring the Causal Relationship Between Circulating Immune Cells and Autoimmune Hepatitis Through Mendelian
Song Leng1, Kefen Wang1, Yujun Shi1
1（ 610041） Department of Respiratory and Critical Care Medicine/Center for High Altitude Medicine/Institutes for Systems Genetics/National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective:
To elucidate the causal relationship between specific immune cells and autoimmune hepatitis (AIH) using a two-sample Mendelian randomization (MR) approach.
Methods:
A bidirectional MR analysis was conducted using data from large publicly accessible Genome-Wide Association Study (GWAS) databases. The inverse variance weighted (IVW) method was employed as the primary method to evaluate the relationship between 731 immune cell traits and AIH. The false discovery rate (FDR) was controlled using the Benjamini-Hochberg correction. Additionally, pleiotropy and heterogeneity tests were performed, and a leave-one-out sensitivity analysis was conducted to further validate the robustness of the results.
Results:
At a significance level of 0.20, it was found that the absolute count of CD28-CD8+ regulatory T-cells (IVW: odds ratio [OR] = 1.486; 95% confidence interval [CI], 1.189-1.859; P < 0.001; P FDR = 0.185), the level of CD28 on CD39+ secreting regulatory T-cells (IVW: OR = 1.194; 95% CI, 1.074-1.328; P = 0.001; P FDR = 0.185), and the level of CD45 on mononuclear myeloid-derived suppressor cells (IVW: OR = 1.243; 95% CI, 1.108-1.394; P < 0.001; PFDR = 0.143) were associated with an increased risk of AIH. The level of programmed death-ligand 1 on CD14+CD16+ monocytes (IVW: OR = 0.849; 95% CI, 0.771-0.935; P < 0.001; P FDR = 0.185) was associated with a reduced risk of AIH.
Conclusion:
Four immune cell phenotypes associated with AIH risk are identified. Further investigation is needed to validate these findings and explore new therapeutic avenues.
